Phase II FORTE: Efficacy of KRd With or Without ASCT in Newly Diagnosed Multiple Myeloma According to Risk Status

May 31 - June 4, 2019; Chicago, Illinois
Including ASCT after KRd induction therapy leads to higher persistent MRD negativity rate and reduces risk of early relapse in NDMM.
Format: Microsoft PowerPoint (.ppt)
File Size: 203 KB
Released: June 3, 2019


Provided by the USF Health

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation

Related Content

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Rebecca Gonzalez, PharmD, BCOP, discusses key pharmacy strategies for management of patients with multiple myeloma in this commentary from Clinical Care Options (CCO)

Rebecca Gonzalez, PharmD, BCOP Released: May 6, 2022

PDF resource that serves as a helpful guide for healthcare professionals on BCMA-targeted therapies in multiple myeloma, from Clinical Care Options (CCO)

Released: May 2, 2022

On-demand webcast on CAR T-cells for patients with hematologic malignancies, from Clinical Care Options (CCO)

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings